Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 25Parkinson Disease 4, Autosomal Dominant Lewy Body 18Multiple Myeloma 13Neoplasms 12Leukemia, Myeloid, Acute 12Ovarian Neoplasms 10Neoplasm Metastasis 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Colorectal Neoplasms 8Melanoma 7Lymphoma, Non-Hodgkin 7Leukemia 7Stomach Neoplasms 6Recurrence 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Adenocarcinoma 5Purpura, Thrombocytopenic, Idiopathic 4Myelodysplastic Syndromes 4Lymphoma, Follicular 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

mirvetuximab soravtansine 2Paclitaxel 2pembrolizumab 1liposomal doxorubicin 1Topotecan 1Saline Solution 1Glucose 1Docetaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Carcinoma, Ovarian Epithelial × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

AbbVie

Phase 3 Completed
453 enrolled 18 charts 1 FDA
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04296890 2024-08-07

SORAYA

ImmunoGen, Inc.

Phase 3 Completed
106 enrolled 14 charts 1 FDA
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡